{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:41:47Z","timestamp":1788370907115,"version":"build-2803163510"},"reference-count":61,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IDR"],"DOI":"10.2147\/idr.s187360","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T09:20:05Z","timestamp":1674724805000},"page":"555-568","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Fischer","family":"Herald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo M","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/antibiotics8030129","volume":"8","author":"Gajd\u00e1cs","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"ref2","unstructured":"Centers for Disease Control and Prevention (US). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention (US); 2019. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed February 27, 2021."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/5584_2020_566","volume":"1323","author":"Behzadi","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"ref4","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: HM Government and Wellcome Trust; 2016. Review on Antimicrobial Resistance, chaired by Jim O\u2019Neill. Available from: https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf. Accessed February 27, 2021."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1056\/NEJMra041359","volume":"352","author":"Jacoby","year":"2005","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e02228","DOI":"10.1128\/AAC.02228-17","volume":"62","author":"Rubino","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","unstructured":"Vabomere\u00ae (meropenem and vaborbactam) [package insert]. In the Treatment of Cutiarm Yourself for Battle Against Serious Gram-Negative Pathogens with Vabomere\u00ae1*. Lincolnshire, IL: Melinta Therapeutics, Inc.; 2021."},{"key":"ref8","unstructured":"World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2021. Available from: https:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/. Accessed January 25, 2021."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medsci6010001","volume":"6","author":"Codjoe","year":"2017","journal-title":"Med Sci (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.43.5.1170","volume":"43","author":"Kohler","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/jac\/35.1.75","volume":"35","author":"Yang","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1128\/AAC.00711-16","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","unstructured":"Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant enterobacteriaceae from United States hospitals (2016\u20132017). Poster presented at the: 4th ASM Microbe Conference; June 2019; San Francisco, CA."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Shortridge D, Deshpande L, Duncan L, Streit J, Castanheira M. Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014\u20132019). Poster presented at the: ID Week 2020; October 2020; Virtual Conference.","DOI":"10.1093\/ofid\/ofaa439.1770"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Shortridge D, Deshpande L, Doyle T, Streit J, Castanheira M. Activity of meropenem-vaborbactam and comparators against globally disseminated Klebsiella pneumoniae sequence type 258. Poster presented at the: ID Week 2020; October 2020; Virtual Conference.","DOI":"10.1093\/ofid\/ofaa439.1769"},{"key":"ref21","unstructured":"Lomovskaya O, Tsivkovski R. Vaborbactam (RPX7009) plus meropenem is active against the newly discovered BKC-1 and FRI-1 carbapenemases. Poster presented at the: 26th Annual European Congress of Clinical Microbiology and Infectious Diseases; April 2016; Amsterdam, Netherlands."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e01694","DOI":"10.1128\/AAC.01694-17","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e01702","DOI":"10.1128\/AAC.01702-17","volume":"62","author":"Rubio-Aparicio","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th. In: CLSI Guideline M100-Ed30. Wayne, PA: Clinical and Laboratory Standards Institute; 2020."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/ofid\/ofu052.267","volume":"1","author":"Griffith","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1128\/AAC.00568-16","volume":"60","author":"Griffith","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1128\/AAC.01713-15","volume":"59","author":"Wenzler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1345\/aph.1E358","volume":"39","author":"Coves-Orts","year":"2005","journal-title":"Ann Pharmacother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/jac\/42.4.563","volume":"42","author":"De Turck","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1177\/0091270009334377","volume":"49","author":"Haroutiunian","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.pediatrneurol.2004.03.014","volume":"31","author":"Nacarkucuk","year":"2004","journal-title":"Pediatr Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1345\/aph.1K079","volume":"41","author":"Spriet","year":"2007","journal-title":"Ann Pharmacother"},{"key":"ref33","volume-title":"Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans)","year":"1993"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.diagmicrobio.2006.06.014","volume":"57","author":"Ong","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/s0149-2918(04)80001-8","volume":"26","author":"Mattoes","year":"2004","journal-title":"Clin Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1128\/AAC.49.1.276-280.2005","volume":"49","author":"Maglio","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e01659","DOI":"10.1128\/AAC.01659-18","volume":"63","author":"Griffith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e01446","DOI":"10.1128\/AAC.01446-17","volume":"62","author":"Sabet","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e01969","DOI":"10.1128\/AAC.01969-17","volume":"62","author":"Sabet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Bhavnani SM, Trang M, Griffith DC, et al. Meropenem-vaborbactam pharmacokinetic pharmacodynamic target attainment analyses as support for dose selection in patients with normal renal function and varying degrees of renal impairment. Poster presented at the: 6th Annual ID Week; October 2017; San Diego, CA.","DOI":"10.1093\/ofid\/ofx163.1382"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"ref42","unstructured":"US Food and Drug Administration (FDA). Complicated urinary tract infections: developing drugs for treatment: guidance for industry; 2021. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070981.pdf. Accessed February 27, 2021."},{"key":"ref43","unstructured":"European Medicines Agency (EMA). Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections; 2021. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/11\/WC500153953.pdf. Accessed February 27, 2021."},{"key":"ref44","unstructured":"FDA. FDA medical review: vabomere (meropenem and vaborbactam), 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209776Orig1s000MedR.pdf. Accessed February 27, 2021."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Wunderink R, Giamarellos-Bourboulis EJ, Rahav G, et al. Meropenem-vaborbactam (VABOMERE) vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Poster presented at the: 6th Annual ID Week; October 2017; San Diego, CA.","DOI":"10.1093\/ofid\/ofx163.1397"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s12325-019-00981-y","volume":"36","author":"Bassetti","year":"2019","journal-title":"Adv Ther"},{"key":"ref48","unstructured":"Alosaimy S, Jorgensen SCJ, Lagnf AM et al. Meropenem vaborbactam in patients with carbapenem resistant enterobacteriaceae gram-negative bloodstream infection: a case series. Poster presented at the: 22nd Annual MAD-ID Meeting; May 2019; Orlando, FL."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/1756287218783871","volume":"10","author":"Ge","year":"2018","journal-title":"Ther Adv Urol"},{"key":"ref50","unstructured":"Avycaz\u00ae [package insert]. Verona, Italy: ACS Dobfar S.p.A.; 2022."},{"key":"ref51","unstructured":"Zerbaxa\u00ae [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; 2022."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.11919\/j.issn.1002-0829.218026","volume":"30","author":"Wang","year":"2018","journal-title":"Shanghai Arch Psychiatry"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ewjm.176.1.51","volume":"176","author":"Jancel","year":"2002","journal-title":"West J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/life10020016","volume":"10","author":"Gajd\u00e1cs","year":"2020","journal-title":"Life (Basel)"},{"key":"ref56","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST criteria; 2021. Available from: http:\/\/www.eucast.org\/. Accessed January 25, 2021."},{"key":"ref57","unstructured":"Recarbrio\u00ae [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; 2022."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e01907","DOI":"10.1128\/AAC.01904-17","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref59","unstructured":"Castanheira M, Woosley LN, Huband MD, Flamm RK. Activity against Enterobacteriaceae isolates, including carbapenem-resistant and carbapenemase-producing isolates, collected in United States (US) hospitals during 2016. Poster presented at the: 21st Annual MAD-ID Meeting; May 2018; Orlando, FL."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref61","author":"Walsh","year":"2019"}],"container-title":["Infection and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87108","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T09:20:14Z","timestamp":1674724814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/clinical-evaluation-of-meropenem-vaborbactam-combination-for-the-treat-peer-reviewed-fulltext-article-IDR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":61,"URL":"https:\/\/doi.org\/10.2147\/idr.s187360","relation":{},"ISSN":["1178-6973"],"issn-type":[{"value":"1178-6973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}